Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Glenmark granted USFDA...

    Glenmark granted USFDA approval on Oral Contraceptives and Leukemia injection

    Written by savita thakur thakur Published On 2016-03-29T10:27:37+05:30  |  Updated On 29 March 2016 10:27 AM IST

    New Delhi: Glenmark Pharmaceuticals has received final approval from the US health regulator USFDA for oral contraceptives and leukemia treatment injection.


    "Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for drospirenone and ethinyl estradiol and for levonorgestrel tablets," it said in a BSE filing.


    Drospirenone and ethinyl estradiol are generic version of Bayer Healthcare's Yasmin tablets and levonorgestrel tablets is generic version of Teva Branded Pharmaceutical Products' Plan B one-Step tablets.


    Glenmark Pharmaceuticals said it also got USFDA's final approval for bendamustine hydrochloride injection, therapeutic equivalent to Cephalon, Inc's Treanda.


    Treanda is used for treatment of patients with chronic lymphocytic leukemia.


    "Today marks Glenmark's first injectable granted approval by the USFDA," the company said.


    Glenmark said under the terms of prior settlement agreement, it will be able to launch bendamustine hydrochloride injection on November 1, 2019, or earlier under certain circumstances.


    "Glenmark was one of the first ANDA (Abbreviated New Drug Applications) applicants to submit a substantially complete ANDA with paragraph IV certification, therefore, Glenmark may be eligible for 180 days of marketing exclusivity for bendamustine hydrochloride for injection, 25 mg/vial and 100 mg/vial," it added.


    According to IMS Health sales data for the 12 months to January 2016, Glenmark said Treanda achieved annual sales of around USD 92.6 million.


    As per IMS data, Yasmin tablets achieved annual sales of around USD 131.7 million and Plan B one-Step tablets achieved annual sales of around USD 45.2 million for the 12 months period ended January 2016.


    The company's current portfolio consists of 112 products authorised for distribution in the US marketplace and 57 ANDA pending approval with the USFDA.


    Shares of Glenmark Pharmaceuticals were trading 0.64 per cent up, at Rs 827.35 in the morning trade on BSE.

    abbreviated new drug applicationsANDAGlenmarkleukemiaoral contraceptivesTevaUS Food and Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok